USA flag logo/image

An Official Website of the United States Government

Bacteriophage therapy for treating A. baumannii infected wounds

Award Information

Department of Defense
Defense Advanced Research Projects Agency
Award ID:
Program Year/Program:
2009 / STTR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
351 W CAMDEN ST STE 100 Baltimore, MD 21201-8603
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 2009
Title: Bacteriophage therapy for treating A. baumannii infected wounds
Agency / Branch: DOD / DARPA
Contract: W81XWH-09-C-0164
Award Amount: $99,991.00


Treatment of bacterial-infected wounds is one the most critical problems in modern medicine, and it presents one of the most significant challenges for US troops during combat operations. The management of bacteria in wounds is complicated by the existence of multidrug-resistant strains and mutants. Therefore, novel modalities for preventing and treating wound infections, one of which may be highly purified and characterized bacteriophage preparations, are required. Lytic phages (i.e., bacterial viruses that infect and lyse their specific bacterial hosts) have been used to treat bacterial infections since their discovery during the first decade of the 20th century. However, their therapeutic use gradually declined in the "Western World" after the advent of antibiotics. At the present time, there is renewed interest in phage-based prophylactic and therapeutic approaches because phages are active against multidrug-resistant, pathogenic bacterial strains and mutants. Our current application proposes to develop a potent lytic bacteriophage preparation/cocktail against A. baumannii - a major wound pathogen of particular concern to the US Army, and an increasingly important public health problem. In addition, we will develop two murine wound-infection models for future studies evaluating our A. baumannii phage cocktail's efficacy in treating A. baumannii wound infections.

Principal Investigator:

Alexander Sulakvelidze
Chief Scientist

Business Contact:

John D. Vazzana
President and CEO
Small Business Information at Submission:

Intralytix, Inc.
The Columbus Center 701 E. Pratt Street Baltimore, MD 21202

EIN/Tax ID: 522112466
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
University of Florida
Division of Sponsored Research
P.O. Box 115500
Gainesville, FL 32611 5500
Contact: Brian Prindle
Contact Phone: (352) 392-3516
RI Type: Nonprofit college or university